Subcutaneous Fat Necrosis During Pembrolizumab Therapy for Metastatic Gastric Cancer: Case Report and Review of the Literature

Abstract

Abstract Background： Recent evidence suggests that immunotherapy is a standard treatment options in gastric cancer. However, immunotherapy may cause many known or unknown adverse events. Case presentation: We recently encountered a case of subcutaneous fat necrosis without pancreatic disease that arose during therapy with pembrolizumab in a patient with metastatic gastric cancer. And subcutaneous nodules started to spontaneously improve within a month of onset and disappeared within half a year with no special treatment. At the last follow-up, the patient did not receive immunotherapy with continuous stable disease. Her survival exceeded 24 months without other treatment. Conclusion: This case may be important for the discovery of rare adverse events in gastric cancer immunotherapy.